Triamcinolone acetonide injectable suspension - Allergan

Drug Profile

Triamcinolone acetonide injectable suspension - Allergan

Alternative Names: Trivaris

Latest Information Update: 05 Aug 2015

Price : $50

At a glance

  • Originator Allergan
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Pregnadienes; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ocular inflammation

Most Recent Events

  • 08 Oct 2013 Biomarkers information updated
  • 17 Jun 2008 Registered for Ocular inflammation in USA (Intravitreous)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top